- About us
- For Dog Owners
- For Horse Owners and Trainers
- For Vets
- For Scientists
Cartrophen Vet (100mg/mL of pentosan polysulfate sodium or PPS) and the concentrated form Cartrophen Equine Forte (250mg/mL of PPS) is a treatment for osteoarthritis or arthritis (OA or also known as degenerative joint disease or DJD) and related musculoskeletal disorders, which provides pain relief by acting on the pathology within the joint that causes pain and lameness.
Cartrophen Vet is classified as a disease modifying osteoarthritis drug (DMOAD) and importantly, it protects and supports the recovery of joint cartilage that is damaged by the arthritic process by its many modes of action.
Cartrophen Vet will benefit acute through to chronic OA due to the progressive nature of this disease. Early intervention with Cartrophen Vet in acute injuries will maximise the restoration of normal connective tissue function.
With 60% of lameness in the horse related to OA, Cartrophen Vet and DMOAD represent the rational approach to the medical treatment of OA.
Cartrophen Equine Forte is currently registered in New Zealand, Australia and U.A.E. It is indicated as an aid in the treatment for non-infectious inflammatory joint disease including osteoarthritis.
The Biopharm recommended dosage for Cartrophen in horses remains 2-2.5mg/kg of PPS, equivalent to 1g of PPS per injection for a 400-500kg horse. The dosage is still administered by way of intramuscular injection on four occasions at intervals of 5-7 days.
Go to downloads for further technical information